5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy

Chemotherapy

Volumn 59, Issue 4, 2014, Pages 273-279

  Lee, Min Geun ^a,d   Lee, Sang Hyub ^a,b   Lee, Seung June ^a,c   Lee, Yoon Suk ^a,c   Hwang, Jin Hyeok ^a,c   Ryu, Ji Kon ^a,b   Kim, Yong Tae ^a,b   Kim, Dong Uk ^e   Woo, Sang Myung ^f  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Hanmaeum Hospital   (South Korea)

^e Pusan National University School of Medicine   (South Korea)

^f National Cancer Center   (South Korea)

Author keywords

FOLFIRINOX; Metastatic pancreatic adenocarcinoma; Second line chemotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; ALANINE AMINOTRANSFERASE; BILIRUBIN; CA 19-9 ANTIGEN; ERLOTINIB; GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG EFFICACY; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892744644     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000356158     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
2. Vincent A, Herman J, Schulick R, et al: Pancreatic cancer. Lancet 2011; 378: 607-620
3. Heinemann V: Present and future treatment of pancreatic cancer. Semin Oncol 2002; 29: 23-31
4. Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as a first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413
5. Haller DG: Future directions in the treatment of pancreatic cancer. Semin Oncol 2002; 29: 31-39
6. Maeda S, Motoi F, Onogawa T, et al: Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: A retrospective study. Int J Clin Oncol 2011; 16: 539-545
7. Katopodis O, Polyzos A, Kentepozidis N, et al: Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: The final results of a phase II trial. Cancer Chemother Pharmacol 2011; 67: 361-368
8. Cereda S, Reni M, Rognone A, et al: Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: A phase II trial. Chemotherapy 2011; 57: 156-161
9. Pelzer U, Kubica K, Stieler J, et al: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26: 4508
10. Xiong HQ, Varadhachary GR, Blais JC, et al: Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008; 113: 2046-2052
11. Gebbia V, Maiello E, Giuliani F, et al: Secondline chemotherapy in advanced pancreatic carcinoma: A multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol 2007; 18:vi124- vi127
12. Gebbia V, Maiello E, Giuliani F, et al: Irinotecan plus bolus/infusional 5-fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: A multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol 2010; 33: 461
13. Tempero MA, Arnoletti JP, Behrman SW, et al: Pancreatic Adenocarcinoma, Version 2.2012: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10: 703-713
14. Dahan L, Bonnetain F, Ychou M, et al: Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010; 59: 1527-1534
15. Boeck S, Heinemann V: The role of secondline chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol 2008; 4: 41-50
16. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med 2011; 364: 1817-1825
17. Assaf E, Verlinde-Carvalho M, Delbaldo C, et al: 5-Fluorouracil/ leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 2011; 80: 301-306
18. Lorgis V, Chauffert B, Gentil J, Ghiringhelli F: Influence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: A retrospective study. Anticancer Res 2012; 32: 4125-4130
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216
20. DTCD NCID: Common Terminology Criteria for Adverse Events v3. 0 (CTAE). Cancer Therapy Evaluation Program 2006
21. Aapro MS, Cameron DA, Pettengell R, et al: EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42: 2433
22. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence- based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205
23. Pliarchopoulou K, Pectasides D: Pancreatic cancer: Current and future treatment strategies. Cancer Treat Rev 2009; 35: 431-436
24. Saad ED, Machado MC, Wajsbrot D, et al: Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002; 32: 35-41
25. Maisey N, Norman A, Hill A, et al: CA19-9 as a prognostic factor in inoperable pancreatic cancer: The implication for clinical trials. Br J Cancer 2005; 93: 740-743
26. Ishii H, Okada S, Sato T, et al: CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 1997; 44: 279
27. Reni M, Cereda S, Balzano G, et al: Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009; 115: 2630-2639
28. Fogelman D, Pathak P, Qiao W, et al: Serum CA 19-9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC). J Clin Oncol 2008; 26: 15514